Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes
- [Correspondence] Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes
- [Correspondence] Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply
- [Editorial] Diabetes education: the key to a brighter tomorrow
- [Comment] Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status
- [Articles] Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
- [Articles] Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis
- [Comment] Trending now: modelling global epidemiology of type 1 diabetes in children and adolescents
- [Articles] Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
- [Personal View] The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery
- [Comment] Setmelanotide for controlling weight and hunger in Bardet-Biedl syndrome
- [In Focus] Lorenz Hofbauer: connecting the unexpected
- [Correspondence] Prequalification of insulin: what is missing?
- [In Focus] Social media and misinformation in diabetes and obesity
- [Correspondence] Out on a limb: living with diabetes in the Philippines during the pandemic
- [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80
- [Comment] COP27 Climate Change Conference: urgent action needed for Africa and the world
- [Country Focus] Gestational diabetes in Australia: navigating a tsunami
- [Comment] The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news
- [Comment] Open-source automated insulin delivery in type 1 diabetes—the evidence is out there